 |
Education: MD, PhD
MRC Laboratory of Molecular Biology
Cambridge University, Cambridge, UK - 1992
Oxford University Medical School, Oxford, UK – 1995
Dr. Camidge joined the University of Colorado as a visiting professor in November of 2005, and was recruited as full-time faculty in October of 2007. |
He is the Director of the Thoracic Oncology Clnical Program and the Program Director for the Thoracic Oncology Clinical and Translational Research Fellowship - a unique training program that provides extended research exposure for U.S. or International Senior Fellows interested in Thoracic Oncology. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012 he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a ‘Luminary in the quest to eradicate lung cancer.’
Research
Dr. Camidge is dual-trained in medical oncology and clinical pharmacology. The Developmental Therapeutics Program acquires access to a broad range of new drugs and in conjunction with the comprehensive Thoracic Oncology Program - including a multi-disciplinary thoracic tumor board, exceptional translational science collaborators and the busy thoracic medical oncology cancer clinics - provides outstanding opportunities to develop new drugs for treating patients with thoracic malignancies. Dr. Camidge is the principal investigator on numerous national and international therapeutic trials.
Funding
Past/present:
-
IASLC Young investigator Award and University of Colorado Lung Cancer SPORE Pilot Project Award: Mechanisms of cell death in non-small-cell lung cancer.
NIH R21: Phase I dose-escalation/randomized Phase II cross-over study of anti-IGF-1R monoclonocal antibody IMC-A12 in patients with advanced non-small cell lung cancer.
Bonnie J. Addario Lung Cancer Foundation: Comparison of ALK detection methodologies; Detecting RET gene rearrangements in NSCLC.
South West Oncology Group: SWOG1300 - A randomized, phase II trial of crizotinib plus pemetrexed versus pemetrexed alone in ALK-positive non-squamous NSCLC patients who have progressed systemically after previous clinical benefit from crizotinib monotherapy (pending).
In
addition, Dr. Camidge has written and is/has been the Principal Investigator on
a number of Investigator Initiated Clinical Trials in the Thoracic Malignancies
and Developmental Therapeutics programs, either taken on and run by the
pharmaceutical industry directly including from Boehringer Ingeleheim (High
Dose Intermittent (HDI) afatinib), or run through UCCC funded by
industry-related grants including from Bayer/Onyx and Merck (sorafenib in
combination with vorinostat); and Ariad (ponatinib).
Selected Publications
Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. Rapid-onset hypogonadism secondary to crizotinib use in
men with metastatic nonsmall cell lung cancer. Cancer 2012 Apr 4. doi:
10.1002/cncr.27450. [Epub ahead of print]
Dasari A,
Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA,
Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients
with advanced solid tumors with expanded cohorts in renal cell carcinoma and
non-small cell lung cancer. Investigational New Drugs 2012 Mar 14. [Epub ahead
of print]
Atherly AJ,Camidge DR. The cost-effectiveness of screening lung cancer patients for
targeted drug sensitivity markers. British Journal of Cancer 2012 Feb 28. doi:
10.1038/bjc.2012.60. [Epub ahead of print]
Doebele RC,
Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, Stopfer P, Kaiser R,
Camidge DR. A phase I, open-label, dose-escalation study of continuous
treatment with BIBF 1120 in combination with paclitaxel and carboplatin in
patients with advanced non-small cell lung cancer. Annals of Oncology 2012;
doi: 10.1093/annonc/mdr596
West HJ,
Camidge DR. Have mutation, will travel: utilizing online patient communities
and new trial strategies to optimize clinical research in the era of
molecularly diverse oncology. J Thorac Oncol. 2012 Mar;7(3):482-4.
Camidge DR,
Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE,
Varella-Garcia M. Correlations between the percentage of tumor cells showing an
ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number,
and response to crizotinib therapy in ALK fluorescence in situ
hybridization-positive nonsmall cell lung cancer. Cancer. 2012 Jan 26. doi:
10.1002/cncr.27411. [Epub ahead of print]
Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt
AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M,
Camidge DR. Oncogene status predicts
patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Cancer. 2012 Jan 26. doi: 10.1002/cncr.27409. [Epub ahead of print]
Weickhardt A,
Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G,
Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW,
Youssoufian H, Adjei A, Camidge DR. A Phase I/II Study of Erlotinib in
Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal
Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung
Cancer. Journal of Thoracic Oncology 2012 Jan 10. [Epub ahead of print]
Doebele RC,
Pilling AB, Aisner D, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman
DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of
Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell
Lung Cancer. Clinical Cancer Research 2012 Jan 10. [Epub ahead of print]
Chow LQ,
Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A,
Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR. A phase I dose-escalation
and pharmacokinetic study of sunitinib in combination with pemetrexed in
patients with advanced solid malignancies, with an expanded cohort in non-small
cell lung cancer. Cancer Chemother Pharmacol. 2011 Oct 12. [Epub ahead of
print]
Shaw AT, Yeap
BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH,
Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K,
Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect
of crizotinib on overall survival in patients with advanced non-small-cell lung
cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet
Oncology 2011 Sep 16. [Epub ahead of print]
Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell
FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J,
Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR. A Randomized, Phase II,
Biomarker-Selected Study Comparing Erlotinib
to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced
Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2011;
29(26):3567-35 73.
Camidge DR,
Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin
WA, Doebele RC. Anaplastic Lymphoma Kinase (ALK) gene rearrangements in
non-small cell lung cancer are associated with prolonged progression free
survival on pemetrexed. Journal of Thoracic Oncology 2011; 6(4):774-780
Camidge DR,
Kono SA, Flacco A, Tan A-C, Doebele RC, Zhou Q, Crino L, Franklin WA,
Varella-Garcia M. Optimizing the detection of lung cancer patients harboring
Anaplastic Lymphoma Kinase (ALK) gene rearrangements potentially suitable for
ALK inhibitor treatment. Clinical Cancer Research 2010; 16(22):5581-5590
Kwak L, Bang
YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa
DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA,
Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ,
Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark
JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. New England Journal of Medicine 2010; 363:1693-1703
